Caas Capital Management LP Invests $300,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Caas Capital Management LP purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 4,700 shares of the biopharmaceutical company's stock, valued at approximately $300,000.

A number of other institutional investors have also recently made changes to their positions in the business. OneDigital Investment Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 1.7% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock valued at $649,000 after acquiring an additional 175 shares during the last quarter. Park Place Capital Corp raised its position in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after purchasing an additional 182 shares during the period. Xponance Inc. raised its position in Halozyme Therapeutics by 1.1% in the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock worth $1,190,000 after purchasing an additional 198 shares during the period. Bessemer Group Inc. raised its position in Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 207 shares during the period. Finally, Parallel Advisors LLC raised its position in Halozyme Therapeutics by 12.5% in the 1st quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock worth $120,000 after purchasing an additional 208 shares during the period. Institutional investors own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday. They issued a "neutral" rating and a $55.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Finally, Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $62.50.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the sale, the director directly owned 28,611 shares in the company, valued at $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,497 shares of company stock valued at $3,533,884. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Down 0.8%

Shares of NASDAQ HALO traded down $0.48 during mid-day trading on Friday, reaching $57.15. 1,242,806 shares of the company were exchanged, compared to its average volume of 1,756,733. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51. The firm has a 50-day moving average of $55.03 and a 200 day moving average of $56.88. The stock has a market cap of $7.04 billion, a price-to-earnings ratio of 15.20, a P/E/G ratio of 0.38 and a beta of 1.15. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same quarter last year, the company earned $0.79 earnings per share. The firm's revenue for the quarter was up 35.2% compared to the same quarter last year. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.